Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
In critically sick patients, it is difficult to determine the ideal regimens for new betalactam/lactamase inhibitors (BLBLIs). Gram-negative bacteria that are multidrug-resistant (MDR) and increase mortality in infected people are a serious challenge to world healthcare.